18F-NaF PET-CT vs 99mTc-MDP SPECT for Detecting Bone Metastasis in Patients With High-Risk Prostate or Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial
Lancet Oncol 2022 Nov 04;[EPub Ahead of Print], F Bénard, S Harsini, D Wilson, K Zukotynski, G Abikhzer, E Turcotte, M Cossette, U Metser, J Romsa, M Martin, C Mar, F Saad, JP Soucy, BJ Eigl, P Black, A Krauze, S Burrell, A Nichol, JC TardifFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.